NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $60.90 +2.06 (+3.50 %) (As of 02/17/2019 09:50 AM ET)Previous Close$60.90Today's Range$58.89 - $60.9252-Week Range$36.92 - $72.81Volume83,101 shsAverage Volume61,909 shsMarket Capitalization$722.03 millionP/E Ratio16.87Dividend YieldN/ABeta2.51 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. Receive ANIP News and Ratings via Email Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A Webwww.anipharmaceuticals.com Phone218-634-3500Debt Debt-to-Equity Ratio1.04 Current Ratio3.34 Quick Ratio2.49Price-To-Earnings Trailing P/E Ratio16.87 Forward P/E Ratio13.41 P/E GrowthN/A Sales & Book Value Annual Sales$176.84 million Price / Sales4.08 Cash Flow$6.2143 per share Price / Cash Flow9.80 Book Value$14.99 per share Price / Book4.06Profitability EPS (Most Recent Fiscal Year)$3.61 Net Income$-1,070,000.00 Net Margins0.23% Return on Equity28.39% Return on Assets12.27%Miscellaneous Employees173 Outstanding Shares11,856,000Market Cap$722.03 million OptionableOptionable ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions What is ANI Pharmaceuticals' stock symbol? ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP." How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals Inc (NASDAQ:ANIP) posted its quarterly earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.34 by $0.21. The specialty pharmaceutical company had revenue of $47.27 million for the quarter, compared to the consensus estimate of $50.70 million. ANI Pharmaceuticals had a return on equity of 28.39% and a net margin of 0.23%. View ANI Pharmaceuticals' Earnings History. When is ANI Pharmaceuticals' next earnings date? ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for ANI Pharmaceuticals. What price target have analysts set for ANIP? 2 analysts have issued twelve-month target prices for ANI Pharmaceuticals' stock. Their forecasts range from $70.00 to $74.00. On average, they expect ANI Pharmaceuticals' share price to reach $72.00 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals. What is the consensus analysts' recommendation for ANI Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals. Has ANI Pharmaceuticals been receiving favorable news coverage? Headlines about ANIP stock have trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of ANI Pharmaceuticals' key competitors? Some companies that are related to ANI Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Arena Pharmaceuticals (ARNA), Akcea Therapeutics (AKCA), Endo International (ENDP), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Insmed (INSM), Madrigal Pharmaceuticals (MDGL), Portola Pharmaceuticals (PTLA) and Xencor (XNCR). Who are ANI Pharmaceuticals' key executives? ANI Pharmaceuticals' management team includes the folowing people: Mr. Arthur S. Przybyl, CEO, Pres & Director (Age 62)Mr. Stephen P. Carey, CFO & VP of Fin. (Age 48)Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 56)Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 47)Dr. David J. Sullivan, VP of Quality Operations Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.54%), Dimensional Fund Advisors LP (4.37%), First Manhattan Co. (1.98%), Investment Counselors of Maryland LLC (1.75%), Phocas Financial Corp. (1.09%) and Northern Trust Corp (0.99%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals. Which institutional investors are selling ANI Pharmaceuticals stock? ANIP stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Nomura Holdings Inc., Algert Global LLC, Virginia Retirement Systems ET AL, BlackRock Inc., Amundi Pioneer Asset Management Inc., Mackay Shields LLC and Smith Asset Management Group LP. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Insider Buying and Selling for ANI Pharmaceuticals. Which institutional investors are buying ANI Pharmaceuticals stock? ANIP stock was bought by a variety of institutional investors in the last quarter, including Investment Counselors of Maryland LLC, Phocas Financial Corp., Ontario Teachers Pension Plan Board, Martingale Asset Management L P, First Manhattan Co., Bessemer Group Inc., Squarepoint Ops LLC and Ranger Investment Management L.P.. View Insider Buying and Selling for ANI Pharmaceuticals. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ANI Pharmaceuticals' stock price today? One share of ANIP stock can currently be purchased for approximately $60.90. How big of a company is ANI Pharmaceuticals? ANI Pharmaceuticals has a market capitalization of $722.03 million and generates $176.84 million in revenue each year. The specialty pharmaceutical company earns $-1,070,000.00 in net income (profit) each year or $3.61 on an earnings per share basis. ANI Pharmaceuticals employs 173 workers across the globe. What is ANI Pharmaceuticals' official website? The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com. How can I contact ANI Pharmaceuticals? ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected] MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ ANIP)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 315 (Vote Outperform)Underperform Votes: 263 (Vote Underperform)Total Votes: 578MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: How Do Investors Open a Backdoor Roth IRA?